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EFFECTS OF IN VIVO TREATMENT WITH FK506 ON NATURAL KILLER CELLS IN RATS I 
FK506, like cyclosporine, diminishes IL-2 receptor expression 
and inhibits IL-2 production by T lymphocytes (1). IL-2 plays 
a crucial role in the generation and function of the large 
granular lymphocytes, also called natural killer cells, which are 
cytolytic in vitro against various tumor cells, some microorga-
nisms, and virally infected cells (2). Because posttransplanta-
tion neoplasia and viral sepsis are common complications after 
transplantation under immunosuppression, we investigated the 
effects of a 4-14-day course of 1.0 mg/kg/day intramuscular 
FK506 on NK cell function in F344 rats. This dose has been 
shown to prevent allograft rejection in MHC- and non-MHC-
incompatible donor-recipient strain combinations (3). Animals 
were sacrificed after 4, 7, or 14 days of treatment, and fresh 
mononuclear spleen cells were isolated after centrifugation on 
Ficoll-Hypaque gradients and passage over nylon-wool columns 
to remove monocytes/macrophages and B cells. NK activity of 
the cell isolates was determined by lysis of NK-sensitive YAC-
1 tumor targets in a 4-hr 5lCr release assay. Antibody-depend-
ent cytotoxicity, which is another measure of NK activity, was 
measured by lysis of NK-resistant P815 tumor targets in the 
presence of rat anti-PSI5 serum. No differences were found in 
NK and ADCC activity after 4 and 7 days of treatment with 
FK506 (Table 1). After 14 days, there was a slight increase in 
NK (17-19%) and ADCC (22%) activity. Because FK506 sup-
presses in vitro mixed lymphocyte reaction responses (1), we 
also performed these NK assays on fresh spleen cells obtained 
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from untreated rats and exposed in vitro to 0.06-250 ng con-
centrations of FK506. There was no effect of FK506 on fresh 
splenic NK cell activity over this wide dose range (Fig. 1). 
The results of flow cytometry studies on splenic cell isolates 
were congruent with the NK assay results. The lack of effect 
of FK506 on NK cell activity correlated with the expression of 
NK-associated cell surface markers. No differences were noted 
in the expression of CD2 (present on NK cells and T cells) and 
3.2.3. (NK cell-specific) after 4, 7, and 14 days of treatment 
(Table 2, data of day 14 not shown). The number of LGL in 
cytospin preparations was not changed after 4 days of FK506 
treatment and only slightly reduced after 7 days. Asialo-GM1-
positive cells (which include NK cells, subpopulations of mac-
rophages, and subsets of T cells) were increased from 25±7 
(% positive cells ±SD) on day 4 to 36±I on day 7; all values 
were within normal range. 
The effect of FK506 on T lymphocytes in the same rats also 
was investigated in order to verify that the dosage regimen was 
therapeutic. This was a positive control for the IL-2-dependent 
T cell mechanism. Fresh mononuclear spleen cells from the 
control and FK506-treated animals were cultured for 3 days at 
a concentration of 1x1Q5 cells/well in the presence or absence 
of Can A (2 ALg/ml) or recombinant IL-2 (103 units/ml) and 
were subsequently pulsed for 8 hr with [3H]thymidine. There 
was no difference in response to stimulation with IL-2 between 
treated and control animals at days 4, 7, and 14 of FK506 
treatment (Fig. 2). However, the response to Con A stimulation 
showed 53% (day 4), 24% (day 7), and 43% (day 14) inhibition 
of proliferation (Fig. 2). 
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TABLE 1. NK and ADCC activities of fresh spleen cells from control 
and FK506-treated rats 
NK activity ADCC (cytotoxicity vs (cytotoxicity vs P81S b) 
Treatment Days of YAC-1) 
of rats treatment Without With 
100:1 a 50:1 anti-P81S PSIS 
antiserum antiserum 
Control 4 31±l.l ' 26±2.7 -1±0.5 46±1 
FKS06 4 28±l.S 22±1.7 -1.4±0.S 38±1.4 
Control 7 36±3.S 27±3.S l.S±0.9 24±1 
FKS06 7 38±1.9 29±3.2 3±0 26±1 
Control 14 47±S 34±4.S -0.S±1.1 41±3.S 
FK506 14 S6±0.3 41±0.6 0.7±0.2 SO±1.1 
" Effector/target ratio. 
b Effector/target ratio of so: l. 
, Mean percentages ±SEM of cytotoxicity from 2 rats in each group. 
d Control rats received 1 ml 0.9% saline/kg/day as a sham injection 
corresponding to the treatment group. 
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FIGURE 1. NK activity of fresh spleen cells from normal F344 rats 
in the presence of FKS06 in varying concentrations. Data represents 
mean percentages ±SEM of cytotoxicity vs Y AC-l. Varying concentra-
tions of FKS06, 0.06-2S0 ng/ml (0 = control) were added to triplicate 
cultures in 100:1 and SO:l effector:target ratios. 
Thus, although lL-2 has also been shown to be important for 
the generation and function of NK cells (2), our experiments 
showed that FK506, which is known to inhibit 1L-2 production 
and receptor expression did not suppress NK or ADCC activity 
with either in vitro or in vivo test systems. The lack of an 
inhibitory effect on NK cytotoxicity correlates well with find-
ings in T cells, in which FK506 also does not interfere with the 
cytotoxic function of effector T cells. 
Some information is available about the effect of other im-
munosuppressive agents on NK activity. While most investi-
gators have found an inhibition of NK and ADCC activity 
during azathioprine therapy, there are conflicting reports about 
corticosteroids and CsA (4-6). Gui et al. (4) reported NK 
inhibition with CsA. However, Muller et al. (6) reported that 
ADCC activity was inhibited during corticosteroid therapy in 
human transplant recipients while NK activity was not. Com-
bined treatment with CsA and corticosteroids in their patients 
suppressed both NK and ADCC activity, and even more acute 
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FIGURE 2. Proliferative response in vitro to Con A and IL-2 stim-
ulation. Animals were treated for 4, 7, or 14 days with FKS06 at 1.0 
mg/kg/day. Controls received 1 ml normal saline/kg/day. Each column 
represents mean 3[Hlthymidine uptake in cpm ±SD from 2 rats in 
each control and 4 or S rats in each FKS06-treated group. 
TABLE 2. Phenotype and percentage of LGL in fresh spleen cells from control and FKS06-treated rats on days 4 and 7" 
Percentage of positive spleen cells 
Surface (CD equivalent) From 4 days From 7 days 
markers 
Control FK506-treated Control FK506-treated 
OX-6 MHC class II 9 11±2b 14 12±1 
OX-8 CD8 43 44±4 41 49±10 
OX-19 CD5 80 84±1 70 83±5 
OX-34 CD2 88 89±1 83 89±6 
OX-39 IL-2 receptor 7 S±l 5 4±3 
OX-41 Macrophages 3 6±1 4 4±1 
W3/25 CD4 41 46±3 38 38±1 
R73 TCR-alpha/beta 74 79±2 67 76±4 
IF4 CD3 73 84±2 83 81±0 
ASGM1 NK cells, subpopulations of 17 2S±7 28 36±O.8 
macrophages, and CTLs 
3.2.3. NK cells 12 13±0 14 16±5 
LGL 4.S±0.7' 4.2S±1.2 S.S±3.S 3.8±0.8 
" Rats were treated for 4 or 7 days with 1 mg/kg/day of FK506 or normal saline. Nylon wool-nonadherent spleen cells were analyzed for the 
expression of cell surface markers by flow cytometric analysis and for the percentage of LGL in Giemsa-stained cytospin preparations. 
b Mean percentage ±SD from two rats in each group. 
, Mean percentage ±SD from two rats in each control group and four rats in each FKS06-treated group. 
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inhibition was found when azathioprine was added as a third 
agent. Such discrepancies may reflect differences in assay.s, 
patient populations, and extent and type of diseases or species 
studied. 
In conclusion, we have shown that NK and ADCC function 
of spleen cells after 4 and 7 days of in vivo treatment with 
FK506 was not affected, whereas a slight increase (19% for NK 
and 22% for ADCC activity) was noted on day 14 compared 
with control animals. The number of NK cells, as determined 
by surface marker phenotype and by morphological analysis of 
the number of LGL, was not different compared with spleen 
cells from control rats. These findings indicate that FK506 has 
little or no effect on NK cell numbers or function in the rat. 
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